PCDHB6

Across TCGA pan-cancer cohorts, PCDHB6 RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated PCDHB6 data layer compared with 8 for mutation status.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PCDHB6 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PCDHB6 expression acts as an unfavorable survival marker, although some lineages such as PAAD and ESCA show a favorable association.

STAD, LUSC, and CESC are the cancer types where PCDHB6 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.502	0.655	<.001	79	view →
LUSC	DFS	Quartile	III,IV	0.209	0.587	.002	39	view →
CESC	DFS	Median	All	0.749	0.884	<.001	36	view →
LIHC	DFS	Median	All	0.290	0.527	.001	17	view →
PAAD	OS	Quartile	All	0.535	0.208	.004	13	view →
ESCA	OS	Median	All	1.000	0.682	.029	12	view →
OV	OS	Median	All	0.369	0.264	.007	12	view →
BRCA	DFS	Median	IV	0.342	0.745	.002	11	view →
TGCT	DFS	Tertile	All	0.617	0.754	.033	10	view →
BLCA	DFS	Median	All	0.212	0.479	.031	9	view →
SCLC	DFS	Median	II,III,IV	0.793	0.230	.003	9	view →
THCA	DFS	Quartile	II,III,IV	0.586	0.904	.014	8	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

PCDHB6–STAD (OS)

Open the STAD breakdown →